15. The formulation of claim **1**, wherein the preservative is sodium benzoate.

16. The formulation of claim **1**, wherein the amount of the preservative is about 0.5 to about 1.2 mg/ml.

17. The formulation of claim **1**, wherein the preservative is methylparaben or propylparaben or salts thereof.

18. The formulation of claim **17**, wherein the amount of the paraben is about 0.1 to about 2 mg/ml.

19. A stable oral liquid formulation, comprising:

(i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;

(ii) a sweetener selected from the group consisting of xylitol, mannitol, sucralose, saccharin, and salts thereof;

(iii) a buffer comprising citric acid and sodium citrate;

(iv) a preservative; and

(v) water;

wherein the formulation is stable at about 25±5° C. for at least 6 months.

20. A stable oral liquid formulation, comprising:

(i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;

(ii) a sweetener;

(iii) a buffer comprising citric acid and sodium citrate;

(iv) a preservative; and

(v) water;

wherein the formulation is stable at about 25±5° C. for at least 6 months.

* * * * *